在严重高甘油度患者中,Ionis Pharmaceuticals报告说,olezarsen降低了三糖体的72%和胰腺炎的85%. Ionis Pharmaceuticals reports olezarsen reduced triglycerides by 72% and pancreatitis by 85% in severe hypertriglyceridemia patients.

艾奥尼斯制药公司报告了针对重症高甘油三血症的月度注射olezarsen的第3期试验结果,显示该药物平均降低了三甘油水平72%,并减少了急性胰腺炎事件的85%,这是该病的首次结果. Ionis Pharmaceuticals reported positive Phase 3 trial results for olezarsen, a monthly injection for severe hypertriglyceridemia, showing a 72% average reduction in triglyceride levels and an 85% decrease in acute pancreatitis events—first such result in the condition. 在接受标准治疗的近1,100名病人中测试的治疗结果也使86%的病人在500毫克/dL以下达到安全三环酸水平。 The treatment, tested in nearly 1,100 patients on standard therapy, also led to 86% achieving safe triglyceride levels below 500 mg/dL. 在美国心脏协会科学会议上介绍了研究结果,并在《新英格兰医学期刊》上发表。 Results were presented at the American Heart Association Scientific Sessions and published in The New England Journal of Medicine. 伊奥尼斯计划在年底前提交FDA补充申请,并正在进行长期扩展研究. Ionis plans to submit an FDA supplemental application by year-end, with a long-term extension study underway.